Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBT (2016 - 2026)

Intellia Therapeutics has reported EBT over the past 12 years, most recently at -$95.3 million for Q1 2026.

  • Quarterly EBT rose 15.04% to -$95.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$394.9 million through Mar 2026, up 20.59% year-over-year, with the annual reading at -$411.8 million for FY2025, 15.35% up from the prior year.
  • EBT was -$95.3 million for Q1 2026 at Intellia Therapeutics, down from -$92.2 million in the prior quarter.
  • Over five years, EBT peaked at -$92.2 million in Q4 2025 and troughed at -$143.7 million in Q1 2022.
  • The 5-year median for EBT is -$104.8 million (2025), against an average of -$112.3 million.
  • Year-over-year, EBT tumbled 211.02% in 2022 and then surged 30.43% in 2023.
  • A 5-year view of EBT shows it stood at -$104.7 million in 2022, then fell by 21.67% to -$127.4 million in 2023, then rose by 1.27% to -$125.8 million in 2024, then grew by 26.69% to -$92.2 million in 2025, then dropped by 3.35% to -$95.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EBT are -$95.3 million (Q1 2026), -$92.2 million (Q4 2025), and -$104.8 million (Q3 2025).